Triple or quadruple tetracycline-based therapies versus standard triple treatment for helicobacter pylori treatment

American Journal of the Medical Sciences

Volumn 338, Issue 1, 2009, Pages 50-53

  Songür, Yildiran ^a   Şenol, Altuǧ ^a   Balkarl, Ayşe ^a   Baştürk, Abdülkadir ^a   Çerçi, Süreyya ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Bismuth; Eradication; Helicobacter pylori; Tetracyclin; Therapy

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; RANITIDINE BISMUTH CITRATE; TETRACYCLINE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIINFECTIVE AGENT; BISMUTH;

ABDOMINAL DISCOMFORT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TASTE DISCRIMINATION; TREATMENT DURATION; VOMITING; ADOLESCENT; DRUG COMBINATION; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BISMUTH; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRACYCLINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68849113749     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31819c7320     Document Type: Article

References (19)

1. Marko D, Calvet X, Ducons J, et al. Comparison of two management strategies for Helicobacter pylori treatment: Clinical study and costeffectiveness analysis. Helicobacter 2005;10:22-32.
2. Rothenbacter D, Ínceoǧlu J, Bode G, et al. Acquisition of Helicobacter pylori infection in a high-risk population occurs within the first 2 years of life. J Pediatr 2000;136:714-716
3. Akin L, Tezcan S, Hasçelik G, et al. Seroprevalence and some correlates of Helicobacter pylori at adult ages in Gülveren Health District, Ankara, Turkey. Epidemiol Infect 2004;132:847-856
4. Can F, Demirbilek M, Selçuk H, et al. [Clarithromycin resistance of Helicobacter pylori strains isolated from antral biopsy specimens]. Mikrobiyol Bul 2004;38:349-353
5. Şimşek H, Balaban YH, GuneşDD, et al. Alarming clarithromycin resistance of Helicobacter pylori in Turkish population. Helicobacter 2005;10:360-361
6. Loffeld RJ, Fijen CA. Antibiotic resistance of Helicobacter pylori: A cross-sectional study in consecutive patients, and relation to ethnicity. Clin Microbiol Infect 2003;9:600-604
7. Onder G, Aydin A, Akarca U, et al. High Helicobacter pylori resistance rate to clarithromycin in Turkey. J Clin Gastroenterol 2007; 41:747-750
8. AltintaşE, Sezgin O, Ulu O, et al. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol 2004;10:1656-1658
9. Malfertheiner P, Megraud F, O'Morain CA, et al. Current concept in the management of Helicobacter pylori infection. The Maastricht III Consensus report. Gut 2007;56:772-781 (Pubitemid 46854190)
10. Coelho LG, Moretzsohn LD, Vieira WL, et al. New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: A pilot study. Aliment Pharmacol Ther 2005;21: 783-787
11. Qasim A, O'Morain CA. Review article: Treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther 2002;16(suppl 1):24-30.
12. Sapone A, Vaira D, Trepidi S, et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Am J Gastroenterol 2003;98:1010-1015
13. Furuta T, Shirai N, Xiao F, et al. Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori in triple therapy. Clin Gastroenterol Hepatol 2004;2:22-30.
14. Uygun A, Kadayifçi A, Safali M, et al. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori. J Dig Dis 2007;8:211-215
15. Mantzaris G, Petraki K, Archavlis E, et al. Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: A 24-month follow-up study. Eur J Gastroenterol Hepatol 2002;14:1237-1243
16. Gené E, Calvet X, Azagra R, et al. Triple vs. quadruple therapy for treating Helicobacter pylori infection: A meta-analysis. Aliment Pharmacol Ther 2003;17:1137-1143 (Pubitemid 36605750)
17. Sezgin O, AltintaşE, Nayir E, et al. A pilot study evaluating sequential administration of a PPI-amoxicillin followed by a PPI-metronidazole-tetracycline in Turkey. Helicobacter 2007;12: 629-632
18. Aydin A, Onder GF, Akarca US, et al. The efficacy of two-week therapy with ranitidine bismuth citrate, amoxicillin and clarithromycin on Helicobacter pylori eradication in clarithromycin-resistant and-sensitive cases. Turk J Gastroenterol 2005;16:203-206
19. Gumurdulu Y, Serin E, Ozer B, et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadruple therapy in Turkey. World J Gastroenterol 2004;10:668-671